813. CAR-T Cell Immunotherapies for Treatment of Cancer and Infectious Diseases
Session: Symposium: Friendly Fire—Immunotherapies and Infectious Diseases
Thursday, October 27, 2016: 3:00 PM
Room: Theater A & B
Susan Prockop, MD, Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY


S. Prockop, Atara Biotherapeutics: Atara Biotherapeutics holds the IND and has a license to develop and commercialize the cell therapy program I will be discussing today. I have no personal conflicts but MSKCC and several MSK investigators currently hold a financial interest in Atara Bioth , I have received no financial or in kind benefit.

<< Previous Presentation | Next Presentation

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.